Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: The closed-loop (CL) system delivers insulin in a glucose-responsive manner and optimal postprandial glycemic control is difficult to achieve with the algorithm and insulin available. We hypothesized that adjunctive therapy with liraglutide, a once-daily glucagon-like peptide-1 agonist, would be more effective in normalizing postprandial hyperglycemia versus insulin monotherapy in the CL system, in patients with type 1 diabetes. Methods: This was a randomized, controlled, open-label, crossover design trial comparing insulin monotherapy versus adjuvant subcutaneous liraglutide 1.2 mg and insulin, using the CL system in 15 patients. Blood glucose (BG), insulin, and glucagon concentrations were analyzed. Results: The liraglutide arm was associated with overall decreased mean BG levels ( P = .0002). The average BG levels from 8:00 pm (day 1) to 9:00 pm (day 2) were lower in the liraglutide arm (144.6 ± 36.31 vs 159.7 ± 50.88 mg/dl respectively; P = .0002). Two-hour postbreakfast and lunch BG profiles were better in the liraglutide arm ( P < .05) and the insulin and glucagon assay values were lower ( P < .0001). Postprandially, the area under the curve (AUC) for 2-hour postbreakfast and lunch BG levels were significant ( P = .01, P = .03) and the AUC for glucagon, postbreakfast ( P < .0001) and lunch ( P < .05), was also significant. The incidence of hypoglycemia did not differ between arms ( P = .83, Fisher’s exact test). Overall, adjunct liraglutide therapy plus CL was well tolerated even with expected side effects. Conclusion: This is a proof-of-concept study showing liraglutide can be a potential adjunctive therapy in addition to CL with insulin to reduce postprandial hyperglycemia in type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 2×
“As opposed to twice daily exenatide, liraglutide is a once-daily injection and better tolerated as shown by the LEAD-6 study.(13) LEAD-6 compared the efficacy and safety between exenatide and liraglutide in type 2 diabetes.”
MethodResultMadsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070861j · Cited by 244 · cited 1×
“Modifications were made to slow subcutaneous tissue absorption, cause reversible albumin binding, and GLP-1 resistance to inactivation by dipeptidyl peptidase-4.(11,12) Unlike exenatide, with a half-life of 2.”
BackgroundPrevention of Nocturnal Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension
Buckingham, B., Chase, H. P., Dassau, E., Cobry, E., Clinton, P., Gage, V., Caswell, K., Wilkinson, J., Cameron, F., Lee, H., et al. (2010) · Diabetes Care · doi:10.2337/dc09-2303 · Cited by 169 · cited 1×
“The system delivers insulin in a glucose responsive manner resulting in periods of euglycemia.(1,2) Current open-loop insulin pump therapy requires meticulous carbohydrate counting and entering of carbohydrate and finger-stick blood glucose (BG) measurements into the system for estimation of insulin bolus amount.”
BackgroundHay, L. C., Wilmshurst, E. G., & Fulcher, G. (2003) · Diabetes Technology & Therapeutics · doi:10.1089/152091503763816427 · Cited by 143 · cited 1×
“In addition, compared to other studies that used only CGM to monitor BG, the current study used CGM as well as Analox BG for confirmation.(30,31) Studies that failed to confirm CGM with BG may have had undetected and underreported hypoglycemia.”
ResultGingras, V., Taleb, N., Roy‐Fleming, A., Legault, L., & Rabasa‐Lhoret, R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13052 · Cited by 113
Frandsen, C. S., Dejgaard, T. F., Holst, J. J., Andersen, H. U., Thorsteinsson, B., & Madsbad, S. (2015) · Diabetes Care · doi:10.2337/dc15-1037 · Cited by 103
Cited by
Gingras, V., Taleb, N., Roy‐Fleming, A., Legault, L., & Rabasa‐Lhoret, R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13052 · Cited by 113
“83 mmol/L) and postprandial BG excursions in comparison with an insulin-only CLS control arm in 15 patients over 24 hours.(109) In a prior study, exenatide (another GLP-1 analog) was compared with pramlintide in CLS settings, both given as injections prior to lunch and dinner.”
The role of automated insulin delivery technology in diabetes
Boughton, C. K., & Hovorka, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06165-w · Cited by 57
Shah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
“59,58 Yet liraglutide had no effect on plasma glucagon during mixed meal tolerance tests, 112 suggesting that GLP-1RAs may not blunt dysregulated glucagon secretion in response to meals.”
InfluentialPramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi, A., Sherr, J., VanName, M., Carria, L., Zgorski, M., Tichy, E., Weyman, K., Cengiz, E., Weinzimer, S., & Tamborlane, W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02265 · Cited by 25
Metadata
- Authors
- Ilkowitz, J. T., Katikaneni, R., Cantwell, M., Ramchandani, N., & Heptulla, R. A.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2016-07-09
- Volume
- 10
- Issue
- 5
- Pages
- 1108-1114
- ISSN
- 1932-2968 (ISSN-L)
- OpenAlex
- W2397471161
- Cited by
- 39
- References
- 6
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial. https://app.cochat.ai/papers/10.1177/1932296816647976
- The paper
- Ilkowitz, J. T., Katikaneni, R., Cantwell, M., Ramchandani, N., & Heptulla, R. A. (2016). Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial. Journal of Diabetes Science and Technology. https://doi.org/10.1177/1932296816647976
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.